Benzinga

Benzinga

Benzinga

jueves, agosto 20

Legend Biotech Corp

LEGNNASDAQ
Trade with Public
Trade with Public
$22.60
0.683.1%
al cierre: Aug 18, 5:00 PM EST
$23.25
1.336.07%
Premercado: 4:13 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadCompararInforme de acciones

Legend Biotech Analyst Price Targets

Wall Street analyst price targets and consensus rating for Legend Biotech (LEGN).

Price Target Range — 12 Quarters

Analyst Consensus — 15 Analysts

11Buy
4Hold
Consensus RatingOverweight# Analysts15Avg. Consensus PT$65Upside to Avg. PT+177.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 12, 2026Morgan StanleyMatthew HarrisonPT RaiseOverweight$48→$49
Aug 12, 2026TD CowenYaron WerberPT CutHold$29→$24
More with Benzinga EdgeGet Access

Analyst Ratings News

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.
Avi Kapoor

PRO
Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49

Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
Benzinga Newsdesk

PRO
TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24

TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
Benzinga Newsdesk

PRO
Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58

RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78

Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved